Top

Published in:

01-07-2013 | Letter to the Editors

Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis

Authors: César Faillace, Jozélio Freire de Carvalho

Published in: Rheumatology International | Issue 7/2013

Excerpt

Reduction of rheumatoid factor (RF) serum levels have been described during anti-TNF treatment in patients with rheumatoid arthritis (RA) [1]. Some studies have shown a relationship between this RF alterations and the clinical response [2]. However, no description on RF fluctuation has been reported with tocilizumab. Only one article defined that remission after tocilizumab is superior in patients with higher titers of IgM RF [3]. …

Bruns A, Nicaise-Roland P, Hayem G, Palazzo E, Dieudé P, Grootenboer-Mignot S, Chollet-Martin S, Meyer O (2009) Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Jt Bone Spine 76:248–253CrossRef

Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A et al (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63:1218–1221PubMedCrossRef

Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Yamasaki S, Nakamura H, Origuchi T, Ueki Y, Migita K, Mizokami A, Aoyagi K, Eguchi K (2011) In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol 21:370–374PubMedCrossRef

Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22:847–861PubMedCrossRef

De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F et al (2003) Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 48:1015–1023PubMedCrossRef

Garcia-Planella E, Domènech E, Esteve-Comas M, Bernal I, Cabré E, Boix J et al (2003) Development of antinuclear antibodies and its clinical impact in patients with Crohn’s disease treated with chimeric monoclonal anti-TNF alpha antibodies (infliximab). Eur J Gastroenterol Hepatol 15:351–354PubMedCrossRef

Viana VS, de Carvalho JF, de Moraes JC, Saad CG, Ribeiro AC, Gonçalves C, Bueno C, Vendramini MB, Bonfá E (2010) Autoantibodies in patients with psoriaticarthritis on anti-TNFα therapy. Rev Bras Reumatol 50:225–234PubMedCrossRef

Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C (2004) Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 6:R264–R272PubMedCrossRef

Ziolkowska M, Maslinski W (2003) Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid Arthritis. Curr Opin Rheumatol 15:267–273PubMedCrossRef

Title: Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis
Authors: César Faillace
Jozélio Freire de Carvalho
Publication date: 01-07-2013
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 7/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-012-2409-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2013

Performance of subjects with knee osteoarthritis during walking: differential parameters

Imaging in rheumatology: ultrasafe + ultrasure = ultrasound

Erratum to: Imaging in rheumatology: ultrasafe + ultrasure = ultrasound

Is phonophoresis effective in the treatment of chronic low back pain? A single-blind randomized controlled trial

Increased levels of matrix metalloproteinase-3 in the sera and synovial fluids of patients with pustulotic arthro-osteitis associated with palmoplantar pustulosis: report of 2 cases

The effect of TNF-alpha blockers on psychometric measures in ankylosing spondylitis patients: a preliminary observation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials